selicrelumab
mAbexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 12, 2014 (NCT02304393)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ro7009789
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03892525 | Phase 1 | Jun 15, 2019 | Roche, The Lymphoma Academic Research Organisation, University of Rennes |
| NCT03424005 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2018 | Roche, Seattle Genetics |
| NCT03193190 | Phase 1/Phase 2 (Phase 2) | Jul 5, 2017 | Roche |
| NCT02760797 | Phase 1 | May 1, 2016 | Roche |
| NCT02665416 | Phase 1 | Jan 25, 2016 | Roche |
| NCT02588443 | Phase 1 | Oct 1, 2015 | University of Pennsylvania |
| NCT02304393 | Phase 1 | Dec 12, 2014 | Roche |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 6 | 5 | 2 | 2014 |
| Seattle Genetics | For profit | 1 | 0 | 1 | 2018 |
| The Lymphoma Academic Research Organisation | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Rennes | Academic/Hospital | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1